Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment
Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment
复制标题
DOI：
10.1016/s1499-3872(12)60144-1
复制
发表时间：
2012-04-01
影响因子：
3.3
通讯作者：
Zhu, Biao
中科院分区：
文献类型：
--
作者：
Wu, Feng;Wu, Min-Jin;Zhu, Biao
背景：持续拉米夫定治疗与YMDD突变的高发生率相关，YMDD突变是耐药的主要原因。本研究探讨了中国慢性B型肝炎患者接受拉米夫定治疗前HBV基因型、HBV-DNA水平、HBeAg状态和血清丙氨酸氨基转移酶（ALT）水平与YMDD突变的关系。方法：共有319例接受拉米夫定治疗一年以上的慢性B型肝炎患者纳入本研究。结果：在319例患者中，137例（42.95%）为B型，182例（57.05%）为C型。在拉米夫定治疗的一年内，多达94例患者（29.47%）发生YMDD突变。HBV基因型B型50例，C型44例（36.50%vs24.18%，P
BACKGROUND: Continuous lamivudine therapy is associated with high rates of YMDD mutations, which are the main causes of drug resistance. The current study explores the association of the emergence of YMDD mutations with pretherapy HBV genotype, HBV-DNA levels, HBeAg status, and serum alanine aminotransferase (ALT) levels in Chinese patients receiving lamivudine therapy for chronic hepatitis B.METHODS: A total of 319 chronic hepatitis B patients who received lamivudine therapy for more than a year were enrolled in this study. YMDD mutations, HBV genotype, HBV-DNA levels, HBeAg status, and ALT levels were determined prior to their lamivudine treatment and every three months for a year of this therapy.RESULTS: Among the 319 patients, 137 (42.95%) were infected with genotype B and 182 (57.05%) with genotype C. Up to 94 patients (29.47%) developed YMDD mutations within one year of lamivudine therapy. Furthermore, 50 patients with HBV genotype B and 44 patients with genotype C developed YMDD mutations (36.50% vs 24.18%, P